Skip to content
lifestyle.brownplanet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oshyn
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
June 2, 2026
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
June 1, 2026
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
May 26, 2026
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
May 5, 2026
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
April 27, 2026
Oshyn Launches AI-First UX Practice to Bridge the Enterprise Gap Between Human Design and AI Agent Discovery
April 21, 2026
Oshyn Debuts “Agentic DXP Development” to Deliver Enterprise-Grade Web Implementations at AI Speed
April 20, 2026
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
April 6, 2026
Oncolytics Biotech® Completes Domicile Change to the United States
April 1, 2026
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
March 19, 2026
1
2
Next Page
→